Vascular Biosciences

Executive Summary

Vascular Biosciences is a private biotechnology company developing its proprietary CAR (CARSKNKDC) peptide platform for targeted drug delivery in pulmonary hypertension, COVID-19, and sepsis. The CAR peptide homes to diseased tissue and enhances uptake of co-administered or conjugated therapeutics, potentially improving efficacy and reducing systemic side effects. Founded in 2004 and headquartered in San Diego, the company has advanced its lead candidate into preclinical development across multiple high-need indications. While no financial details or clinical-stage data are publicly available, the platform's versatility and disease-targeting mechanism position it as a potential enabler of repurposed and combination therapies. Upcoming milestones include regulatory filings and initial clinical data readouts, which will be critical to assessing the platform's clinical viability and commercial potential. The company operates in the diagnostics category but its therapeutic applications broaden its scope.

Upcoming Catalysts (preview)

• Q3 2026IND filing for pulmonary hypertension program65% success
• Q4 2026Preclinical proof-of-concept data in COVID-19 or sepsis models50% success
• TBDStrategic partnership or licensing agreement for CAR platform40% success